Clinical Trials Logo

Filter by:
NCT ID: NCT06292598 Not yet recruiting - Narcolepsy Type 1 Clinical Trials

Bacterial Translocation and Gut Microbiota in Type 1 Narcolepsy Patients Versus a Control Population

NARCOBIOTE
Start date: May 2024
Phase:
Study type: Observational

Narcolepsy type 1 (NT1) is a rare disease characterized by severe drowsiness, cataplexy, hypnagogic hallucinations, sleep paralysis, poor night sleep, and often obesity. NT1 is caused by irreversible loss of orexin (ORX)/hypocretin neurons in the lateral hypothalamus with decreased ORX levels in the cerebrospinal fluid (CSF). Although the underlying process leading to this destruction remains unclear; an autoimmune origin is suspected. The study authors recently compared the bacterial communities of the fecal microbiota of NT1 patients and control subjects. Initial results demonstrated a difference in overall bacterial community structure in NT1 compared to controls, as assessed by beta diversity, even after adjusting for body mass index (BMI). The Shannon biodiversity index was also correlated with the duration of NT1 disease. However, no association was found between the structure of the microbial community and the clinical characteristics of NT1 patients. In 2022, a second study from the SOMNOBANK cohort on a larger population confirmed these results, showing dysbiosis between NT1 patients and the control population. The altered intestinal microbial diversity supports the important role of the environment in the development and pathogenesis of NT1. Other studies have established a link between dysbiosis, intestinal permeability and inflammation in other neuroimmune pathologies. Currently, no study has focused on these phenomena of bacterial translocation, intestinal permeability and immune activation linked to the microbiota in type 1 narcolepsy patients. The study hypothesis is that NT1 patients with dysbiosis in their intestinal microbiota also present a bacterial translocation with an intestinal origin, leading to a systemic inflammatory syndrome favoring an autoimmune damage destroying hypocretin neurons in the hypothalamus. The study authors suspect that microbial elements (DNA) involved in the autoimmune process could be detected in the CSF. This bacterial translocation could vary over time depending on: i) the progression of the disease and its management; ii) changing dysbiosis and: iii) the increase in intestinal permeability and inflammation.

NCT ID: NCT06292572 Not yet recruiting - Retinal Detachment Clinical Trials

Clinical Characteristics and Surgical Outcomes of the Fellow Eye in Bilateral Retinal Detachments

Start date: March 1, 2024
Phase:
Study type: Observational

To assess the clinical features and the surgical outcomes of RD repair surgery of the fellow eye in bilateral retinal detachments

NCT ID: NCT06291467 Not yet recruiting - Depression Clinical Trials

Plasma Beta-endorphin Levels and Suicidal Behavior

BEST
Start date: March 2024
Phase: N/A
Study type: Interventional

It is an interventional research, monocentric, which involves only minimal risks and constraints. Psychological pain is closely associated with suicidal ideation (SI) and suicidal behavior, regardless of the severity of the depression. The psychological pain being regulated by the opioidergic system, it seems that a dysfunction of this system exists in suicidal attempters. The aim of this study is to explore the association between levels of β-endorphin and suicidal behavior. The research team will measure plasma levels of β-endorphin in patients hospitalized for suicide attempt (SA) within 72 hours and compare them to those of patients hospitalized for current major depressive episode (EDC) without any lifetime history of SA. In order to follow the kinetics of β endorphin levels, The research team will carry out two measurements: at inclusion and on day 7 (+/- 2 days) of inclusion. The main objective is to compare plasma β-endorphin levels in patients hospitalized following a recent SA (≤72 hours) and in patients hospitalized for an EDC without lifetime history of SA.

NCT ID: NCT06291350 Not yet recruiting - Clinical trials for Pemphigoid, Benign Mucous Membrane

Peridontal and Intestinal Microbiota in Patients With Gingival Scarring Pemphigoid

MICROPC
Start date: June 15, 2024
Phase:
Study type: Observational

Patients suffering from Mucous Membrane Pemphigoid with desquamative gingivitis (MMPg) generally present a more degraded periodontal condition compared with controls. Bullous disease could represent a risk factor for plaque-induced periodontal disease, and vice versa. Indeed, the dysbiotic periodontal microbiota could aggravate the gingival damage specific to MMP, either directly by activating inflammatory pathways, or indirectly by degrading cellular and matrix components. On the other hand, areas of erosive gingiva generated by the autoimmune process could increase the virulent power of periodontal pathobionts, by representing accessible, nutrient-rich connective surfaces. Moreover, in recent years, bacterial studies based on a high-throughput metagenomic approach have suggested the existence of a relationship between the oral and intestinal microbiota in patients with degraded periodontal conditions and suffering from autoimmune inflammatory diseases (inflammatory bowel disease, acute graft-versus-host disease). This relationship can also be envisaged in MMPg patients who meet the conditions that allow this type of pathological process to occur: autoimmune disease; disruption of the gingival epithelial barrier in erosive gingival areas (increasing the risk of antigen exposure); large amounts of thick plaque; degraded periodontal condition with the presence of numerous periodontal pockets from which periodontopathogenic bacteria can translocate intra-tissularly and cause distant adverse consequences. The main aim of this observational, multicentre, case-control, matched study is to compare the composition of the periodontal microbiota between MMPg patients and control patients (arm 2 and arm 3). The secondary objectives are to compare the composition of periodontal and intestinal microbiota in cases and control patients (arm 2 and arm 3), to compare periodontal microbiota composition in cases and control patients (arm 2) according to periodontitis severity, and to compare gut microbiota composition between cases and control patients (arm 2 and arm3). To date, no such study exists.

NCT ID: NCT06291012 Not yet recruiting - Child, Only Clinical Trials

Stopping Pneumonia Antibiotherapy Regimen Early

SPARE
Start date: September 1, 2024
Phase: Phase 4
Study type: Interventional

The hypothesis for this trial is that an antibiotic strategy for the management of non-severe community-acquired alveolar pneumonia in children aged 3 to 59 months, including amoxicillin 80-100 mg/kg/day for at least 3 days in case of rapid response and 5 days in case of delayed response, would not be inferior to current French recommendations (antibiotic therapy for 5 days in case of rapid response and 7 days in case of delayed response) in terms of treatment of failure rate at 7 days.

NCT ID: NCT06290999 Not yet recruiting - Pulsatile Tinnitus Clinical Trials

Study of Multifrequential Impedancemetry in Pulsatile Tinnitus

MADMAN
Start date: March 15, 2024
Phase:
Study type: Observational

This study intended to search for a relationship between the multifrequential admittancemetry and the pulsatile tinnitus.

NCT ID: NCT06289361 Not yet recruiting - HIV Infections Clinical Trials

Cohort IMEA 070 -Lenacapavir Compassional

Start date: April 1, 2024
Phase:
Study type: Observational

Immunovirological follow-up and safety of HIV-infected patients receiving lenacapavir under compassionate access in France between 01/01/2021 and 12/31/2023

NCT ID: NCT06289348 Not yet recruiting - Phenylketonuria Clinical Trials

Announcement of Rare Metabolic Diseases in Systematic Newborn Screening: the Phenylketonuria Experience.

ANNPHE
Start date: April 2024
Phase:
Study type: Observational

The aims of this collaborative, interdisciplinary research project are to understand and describe the psychological impact of the announcement of a rare, serious disease present since birth and detected in the context of the systematic neonatal screening (DNS), in terms of the parents' experience, but also on the part of the medical team, in order to improve its process and the support it provides for the announcement of the diagnosis.

NCT ID: NCT06286683 Not yet recruiting - Clinical trials for Subarachnoid Hemorrhage

Impact of Early Mobilization on SAH Patients Physiological Parameters

MOBALPAH
Start date: March 2024
Phase:
Study type: Observational

The aim of the study is to evaluate the physiological response to out-of-bed mobilization in patients admitted to the intensive care unit for subarachnoid hemorrhage. More specifically, the aim is to measure the impact on cerebral perfusion, lung aeration, cardiovascular and respiratory parameters.

NCT ID: NCT06285513 Not yet recruiting - Shock Clinical Trials

Cardiovascular Metabolic Remodeling in Shock

METASHOCK
Start date: September 2024
Phase:
Study type: Observational

The aim of the study is to increase our knowledge of energy dysfunction in the cardiovascular dysfunction observed during shock states by analysing the omics molecules involved.